Press releases
- Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
- Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
- Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
- Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
More ▼
Key statistics
On Monday, Poseida Therapeutics Inc (2RZ:FRA) closed at 2.79, -26.86% below its 52-week high of 3.82, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.76 |
---|---|
High | 2.79 |
Low | 2.75 |
Bid | -- |
Offer | -- |
Previous close | 2.91 |
Average volume | 50.00 |
---|---|
Shares outstanding | 96.96m |
Free float | 70.08m |
P/E (TTM) | -- |
Market cap | 323.84m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 14:29 BST.
More ▼